Investigating how IL-1 beta inhibition affects blood vessel inflammation in patients with specific genetic mutations.
Effects of IL-1 beta inhibition on vascular inflammation in TET2 clonal hematopoiesis
This study is looking at how inflammation affects heart health in people with a specific genetic change called TET2 clonal hematopoiesis, and it’s for those who have had heart problems before; participants will receive either a treatment to lower inflammation or a placebo, and we’ll see if this helps improve their heart health over a year.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11048029 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of inflammation in cardiovascular disease risk among individuals with a specific genetic mutation known as TET2 clonal hematopoiesis. The study will enroll participants with a history of heart issues and compare levels of vascular inflammation between those with and without this mutation. Participants will receive either a treatment that inhibits IL-1 beta or a placebo, and their vascular inflammation will be assessed using advanced imaging techniques over a 12-month period. The goal is to determine if the treatment can effectively reduce inflammation and improve heart health.
Who could benefit from this research
Good fit: Ideal candidates are individuals with a history of cardiovascular disease and the TET2 clonal hematopoiesis mutation.
Not a fit: Patients without a history of cardiovascular disease or those without the TET2 mutation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for reducing cardiovascular disease risk in patients with TET2 mutations.
How similar studies have performed: Previous research has shown promising results in targeting inflammation for cardiovascular disease, suggesting potential success for this approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Toribio, Mabel — Massachusetts General Hospital
- Study coordinator: Toribio, Mabel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.